Nebulizers in pulmonary physical therapy: market overview and selection criteria
DOI:
https://doi.org/10.24959/sphhcj.24.331%20Keywords:
nebulizers; physical therapy; pulmonology; chronic obstructive pulmonary disease; range of medical equipment; market analysisAbstract
Aim. To analyze the market of nebulizers used to provide physical therapy for patients with pulmonary diseases in Ukraine.
Materials and methods. The study was based on scientific publications, data from the State Register of Medical Devices of Ukraine, data from the websites of pharmacy chains, and the results of a survey of pharmaceutical professionals. The research methods were scientific generalization, comparison, graphical and mathematical analysis, and questionnaires.
Results. The data on the technical characteristics of modern nebulizers and the peculiarities of their use in physical therapy of different groups of patients were summarized. The analysis of the range of nebulizers in the pharmaceutical market of Ukraine showed that the dominant models were compressor-type models (almost 68 % of the range). The share of ultrasonic and mesh nebulizers was insignificant – 26 % and 6 %, respectively. Among the manufacturers of compressor nebulizers, the main share in the assortment belonged to models made in Ukraine (28 % of the subgroup assortment). In general, this type of nebulizers was supplied to the market by manufacturers from 10 countries. The share of domestic models in the ultrasonic nebulizer assortment was 23 %, while the remaining 6 countries accounted for 77 % of the range, respectively. Mesh nebulizers were available from 3 countries (Germany, Japan, China). It was found that the inhaler with the best reviews among doctors was the ArhiMED MESH Pro mesh nebulizer model (Poland), the second place was occupied by the B.Well pro-115 ultrasonic model (Switzerland), and the third place was occupied by the Medisana IN 525 compressor-type model (Germany). The analysis of price characteristics of nebulizers showed that the greatest fluctuations in cost indicators were experienced by the Medisana IN 510 compressor-type models (Germany) – the value of the price growth index was 2.4. Based on the calculations of the affordability index, it was determined that the Beurer IH 21 nebulizer (Germany) with an affordability index value of 1.43 was the most affordable during the period of analysis. The results of the survey of pharmacists involved in the selection of nebulizers for pharmacy visitors showed that compressor-type nebulizers were in the greatest demand, and the price category from UAH 1000 to UAH 1500 was acceptable for consumers to purchase this type of medical equipment.
Conclusions. The results of the analysis indicate the physical availability and a wide range of nebulizers for providing physical therapy to patients with pulmonary diseases. However, it has been determined that to ensure the affordability of these devices, it is necessary to implement government measures and programs for the relevant groups of patients. In addition, it can be argued that developing and implementing standardization of criteria for assessing the effectiveness of various types of nebulizers, as well as determining the long-term impact of nebulizer therapy on patients with respiratory diseases, is relevant.
References
Barjaktarevic, I., Milstone, A. (2020). Nebulized Therapies in COPD: Past, Present, and the Future. Int. J. Chron. Obstruct. Pulmon. Dis, 15, 1665- 1677. doi: 10.2147/COPD.S252435.
Kotvitska, A., Bezpala, Y., Baranova, I., Khushvakhtzoda, Q. (2022). Study οf Commodity Aspects οf Compressor Nebulizers in Ukraine. Pharmakeftiki, 34(4), 156–165.
Sorino, C., Negri, S., Spanevello, A., Visca, D. (2020). Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur. J. Intern. Med, 75, 15-18.
Leung, A., Wong, A., Hon Kam. (2018). Community-Acquired Pneumonia in Children. Recent Pat. Inflamm. Allergy Drug Discov. Vol. 12(2). Р. 136-144. doi: 10.2174/1872213X12666180621163821.
Sauteur, P. M. M. (2020). Challenges and Progress Toward Determining Pneumonia Etiology. Clin. Infect. Dis, 71(3), 514-516. doi: 10.1093/cid/ciz879.
Khalil, M., Hajj, R., Zaraket, H. (2022). Efficacy of Nebulized Therapy in Respiratory Disease Management. Frontiers in Pharmacology, 13, 859491.
Yang, C., Yu, C. (2021). Inhaled Therapy for COPD: Nebulizers Versus Dry Powder Inhalers. International Journal of Chronic Obstructive Pulmonary Disease, 16, 3001-3011.
Global Initiative for Asthma (GINA) (2023). Global Strategy for Asthma Management and Prevention. Available at: https://www.knowledge-action-portal.com/en/content/global-strategy-asthma-management-and-prevention-0.
Chong, J., Chen, W. (2021). Advances in Nebulizer Therapy for Respiratory Diseases. Current Opinion in Pulmonary Medicine, 27(3), 200-206.
Somasundaram, N., Ramalingam, R. (2019). Effectiveness of Nebulizer Therapy in Pulmonary Rehabilitation Programs for Patients with COPD. European Respiratory Journal, 54(1), PA4964.
Berlinski, A. (2020). Nebulized Drug Delivery in Pediatric Patients: How, Why, and What for. Paediatric Respiratory Reviews, 35, 1-7.
Heijerman, H. G., McKone, E. F., Downey, D. G. (2020). Efficacy and Safety of Inhaled Therapy for Cystic Fibrosis. European Respiratory Journal, 56(5), 1902624.
Jones, P. (2019). Technological Advances in Nebulizer Therapy: A Comprehensive Review. Respiratory Medicine, 78(2), 245-258.
Brown, T., Lee, J., Smith, K. (2021). Efficiency of Compressor Nebulizers in COPD Management: A Clinical Study. Pulmonary Therapeutics Journal, 56(2), 145-159.
Smith, A., Brown, T., Johnson, K. (2020). Comparative Analysis of Nebulizer Efficiency in Respiratory Therapy. Journal of Medical Devices, 45(3), 123-134.
Roca, P., Martinez, L., Gomez, A. (2019). Advances in Mesh Nebulizer Technology for Respiratory Diseases. European Respiratory Review, 28(151), 190056.
Wang, H., Liu, Y., Zhang, Q. (2022). Particle Size Distribution and Its Impact on Drug Delivery in Nebulization Therapy for COPD and Asthma Patients. Journal of Aerosol Medicine, 35(1), 34-45.
Hamelmann, E., Mutius, E., Bush, A., Szefler, S. J. (2020). Addressing the Risk Domain in the Long-Term Management of Pediatric Asthma. Pediatr. Allergy Immunol, 31(3), 233-242. doi: 10.1111/pai.13175.
Bonnie, W. R. (2020). Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. European Respiratory Review, 29(158), 190091.
EN 13544-1:2007+A1:2009(MAIN). Respiratory therapy equipment. Part 1: Nebulizing systems and their components. Available at: https://standards.iteh.ai/catalog/standards/cen/5d103313-74c1-4854-b8cd-.
Derzhavnyi reiestr medychnykh vyrobiv. Available at: https://mozdocs.kiev.ua/medvyrob.php?vyrobname=%B2%ED%E3%E0%EB%FF%F2%EE%F0®num=&manufacturer=&zayavitel=&page=1.
Naikrashchyi inhaliator nebulaizer – vidhuky likariv, reitynh top 10 nebulaizeriv (inhaliatoriv). Available at: https://babymedical.com.ua/uk/samyj-luchshij-ingalyator-nebulajzer-otzyvy-vrachej-rejting-top-10-nebulajzerov-ingalyatorov/.
Derzhavna sluzhba statystyky Ukrainy. Available at: http://www.ukrstat.gov.ua/.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).